Toxicokinetic and mechanistic basis for the safety and tolerability of liposomal amphotericin B
In: Expert opinion on drug safety, Jg. 12 (2013), Heft 6, S. 881-895
academicJournal
- print, 130 ref
Zugriff:
Introduction: Amphotericin B (AmB) was first approved by the US Food and Drug Administration in 1959 with sodium deoxycholate (DAmB, Fungizone®). Extensive toxicities associated with the drug led to the development of lipid formulations of AmB, including liposomal amphotericin B (L-AmB, AmBisome®). Phase I studies as well as comparative Phase III clinical trials indicate that L-AmB is associated with less nephrotoxicity and reduced infusion-related toxicity. There is, however, no recent comprehensive review of the safety and tolerability of L-AmB. Areas covered: This article reviews the safety, tolerability and the mechanisms of the major toxicities associated with L-AmB, including nephrotoxicity, infusion-related reactions (IRRs), anemia and thrombocytopenia, and hepatic abnormalities. The article further discusses the mechanism of action and pharmacokinetics of L-AmB. Expert opinion: L-AmB is a broad-spectrum antifungal agent that has significantly reduced toxicities compared to its predecessor, DAmB.
Titel: |
Toxicokinetic and mechanistic basis for the safety and tolerability of liposomal amphotericin B
|
---|---|
Autor/in / Beteiligte Person: | LOO, Angela S ; MUHSIN, Saif A ; WALSH, Thomas J |
Link: | |
Zeitschrift: | Expert opinion on drug safety, Jg. 12 (2013), Heft 6, S. 881-895 |
Veröffentlichung: | London: Informa, 2013 |
Medientyp: | academicJournal |
Umfang: | print, 130 ref |
ISSN: | 1474-0338 (print) |
Schlagwort: |
|
Sonstiges: |
|